Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Key information in the notes prepared by L.L.Bradford and recent PRs
1) During August 2012, a subsidiary (“Subsidiary”) of the Company entered into an Investors’ General Agreement and
Investment Platform Provider Business Agreement (hereafter the “Investor Agreement”). The Investor Agreement
describes the profit sharing between the investors and the Subsidiary and provides for weekly payment of those profits.
The agreement will be ongoing for five year
2) All profits generated from the use of the funds will be deposited in full to the bank of Bergamo’s European subsidiary company. These profits will be divided equally between National Wealth International Ltd. and the European subsidiary company of Bergamo Acquisition pursuant to the profit-sharing agreement between the parties.
3) Hillard Herzog, President and CEO of Bergamo, stated, “By contractual agreements, the funds deposited into our European subsidiary’s bank account are exclusively authorized for the investment program in place with National Wealth International. We requested examination by our corporate certified public accounting firm to erase any doubt that Bergamo Acquisition is able to move directly ahead with its investment program.”
4) L.L. Bradford has reviewed and verified all the original documents and the original bank deposit statement from HSBC. These original documents provided the location, account number and dollar value of deposits, and were signed & sealed by two bank officers for authenticity. L.L. Bradford finally confirmed Bergamo Acquisition’s current financial agreements. For further information on the recently announced investment agreement, review the press release issued by Bergamo Acquisition on January 10, 2013 (http://finance.yahoo.com/news/bergamo-acquisition-corp-signs-investment-165821767.html).
The letter of confirmation written by L.L. Bradford, together with redacted versions of all original documents reviewed by the CPA firm, has been posted on the OTC Markets website (www.otcmarkets.com/stock/BGMO/filings) as well as the website of Bergamo Acquisition (www.BergamoCorp.com). Bergamo Acquisition has posted redacted versions in conformity to nondisclosure and non-circumvent agreements with its partners.
There are lies being told, but it`s not from BGMO or L.L. Bradford. The lies are being spewed anonymously on the internet everyday !!!!
Every time I read the financial statement and the notes prepared by L.L. Bradford, I shed a tear of joy !!!
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=92172
Timing is everything !!!
I will believe ( and trust ) the independent accounting firm of L.L.BRADFORD on the numbers
THE NUMBERS DON'T LIE BUT ANONYMOUS INFORMATION ON THE INTERNET DOES $$$$$$$
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=92172
THE INDEPENDENT ACCOUNTING FIRM OF L.L.BRADFORD WOULD NOT RISK THEIR BUSINESS LICENCE FOR HERZOG OR ANYONE ELSE BY PRODUCING A COMPILED FINANCIAL THAT IS ERRONEOUS OR MISLEADING
For the period from January 1, 2012, through September 17, 2012, the company reported net income of $88,439,000, or $0.53 per share, on consolidated revenues of $283,952,000.
THERE IS THE PROOF BGMO HAS THE $88 MILLION AND MORE TO COME $$$$$$$$$
Bradford`s disclaimers in the cover letter does not give them legal right to produce a financial statement that is false or misleading
http://www.bullivant.com/Accountants-risks-presented-in-the-preparation
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=92172
Compiled financial statements, also referred to as unaudited statements, are not audited adequately and no opinion on the quality of the financial statements is given. Statements and guarantees about the accuracy of the financial statements are much less than that given by certified financial statements. Accountants that compile a company's financial statements are not required to verify or confirm the records and they do not need to analyze the statements for accuracy. However, in the event that an accountant finds erroneous, misleading or incomplete information in the financial statements they must notify management or abandon their involvement in assessing the company’s financial statements. The accountant who is appointed to compile a company’s financial statement must be familiar with the company and its main business processes.
Honesty is always the best policy ( Just keeping them honest )
Looks like I hit the nail on the head, the ghost writer has disappeared, and the SEC impersonating conman Hal Wolfe has showed up.
Impersonating a S.E.C. employee is a Federal criminal offence, BGMO lawyers and the S.E.C. are well aware of this con artist and his co-conspirators charades.
Anyone else who would like to report this con artist Terry Thompson ( Hal Wolfe ) to the S.E.C. for violations of the Federal criminal laws, follow the link below
Also Global Arena was not an Incorporated company in the year 2000 to 2005, this con artist should be reported to the S.E.C. by all shareholders.
http://www.linkedin.com/profile/view?id=231384327&authType=name&authToken=Aole&goback=%2Ewvp_*1_*1_*1&trk=wvmx_p
http://www.sec.gov/news/press/2009/2009-39.htm
http://law.onecle.com/michigan/750-michigan-penal-code/mcl-750-217c.html
BGMO is as real as a heart attack
Just Keeping Them Honest
Right on the OTC short report website
Any short sale that is not declared is a naked short. The shorts being reported on the OTC short report don't show up on any short interest list.
OTCShortReport.com provides updated naked short selling numbers, as reported by FINRA. The data covered here is used for informational purposes only. The site is not intended to give advice to companies on short selling and or any investment recommendations. Please read our disclaimers for further information.
And if you tracked the naked short selling on BGMO for the last couple of years, you would know that number of naked shorts is huge.
http://otcshortreport.com/blog/daily-otc-short-report/daily-naked-short-numbers-for-july-25-2013/
The Hal Wolfe conman gang isn't working overtime because all the employees have quit writing, the quality of the penmanship is embarrassing now !!!!
Where is Casper the unfriendly ghost writer !!!
LOL !!!
Naked shorts are on fire !!!
http://otcshortreport.com/index.php?index=BGMO#.UfhZco1zGSp
Bergamo Acquisition Corp. (BGMO) -OTC Markets 0.0275 Up 0.0125 + ( 83.33% )
It's not a matter of if BGMO will acquire approximately 70% of VSTA it just a matter of when.
We know the hold period of the of the initial profit of $88 million earned from the first tranche of investment funds of US $500 million will be up in a couple of months, but obviously BGMO and VSTA management believe the acquisition of VSTA will happen before then.
Quote:
In addition, the parties have agreed that no less than US $88 million, or its equivalent value in Euros, shall remain on deposit in the account of Bergamo Acquisition’s European subsidiary for a period of one year. This amount represents the initial profit earned from the first US $500 million cash-backed securities investments entered into between the parties previously, as set forth in Bergamo’s most recent consolidated financial report compiled by L.L. Bradford & Company LLC, a public accounting firm based in Nevada
Timing is everything
FACTS !!!!
Another thing missing is the quality but misleading penmanship, that has been spewed on the internet for years.
Congratulations to all the shareholders, that didn't listen to the B/S on the internet and held onto their stock
Great job Mr. Herzog and Mr. Parekh, and thank you for not quitting on the shareholders
This is when Mr. market will buy, after the fact and that is when I will sell to Mr. market !!!
The billion dollar question is !!
When will BGMO close acquisitions, buy back,tender, and pay a dividend
That's when serious money will be made on the stock
Inquiring minds want to know
HSBC USD 1,000,000,000,00
Keep eyes open
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=98483
It's not a matter of if BGMO will acquire approximately 70% of VSTA it just a matter of when.
We know the hold period of the of the initial profit of $88 million earned from the first tranche of investment funds of US $500 million will be up in a couple of months, but obviously BGMO and VSTA management believe the acquisition of VSTA will happen before then.
Quote:
In addition, the parties have agreed that no less than US $88 million, or its equivalent value in Euros, shall remain on deposit in the account of Bergamo Acquisition’s European subsidiary for a period of one year. This amount represents the initial profit earned from the first US $500 million cash-backed securities investments entered into between the parties previously, as set forth in Bergamo’s most recent consolidated financial report compiled by L.L. Bradford & Company LLC, a public accounting firm based in Nevada
Timing is everything
FACTS !!!!
I will believe ( and trust ) the independent accounting firm of L.L.BRADFORD on the numbers
THE NUMBERS DON'T LIE $$$$$$
( FACTS NOT OPINIONS )
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=92172
THE INDEPENDENT ACCOUNTING FIRM OF L.L.BRADFORD WOULD NOT RISK THEIR BUSINESS LICENCE FOR HERZOG OR ANYONE ELSE BY PRODUCING A COMPILED FINANCIAL THAT IS ERRONEOUS OR MISLEADING
National Wealth International Ltd. has provided Bergamo Acquisition's wholly owned European subsidiary cashed-backed securities consisting of three separate tranches of 500 Million US Dollars issued through HSBC Bank, one of the world's largest banking and financial services organizations. These funds will remain on deposit in accounts held by Bergamo Acquisition's European subsidiary.
For the period from January 1, 2012, through September 17, 2012, the company reported net income of $88,439,000, or $0.53 per share, on consolidated revenues of $283,952,000.
THERE IS THE PROOF BGMO HAS THE $88 MILLION AND MORE TO COME $$$$$$$$$
Bradford`s disclaimers in the cover letter does not give them legal right to produce a financial statement that is false or misleading
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=92172
Thanks for proving my point no one gives a rats azz what happened before 2012, what happened after Sept. 2012 is all that matters to shareholders now
UPDATE: VistaGen Announces $36 Million Strategic Financing Agreement
April 10, 2013
Proceeds Will Accelerate Stem Cell Technology-Based Drug Rescue, Predictive Toxicology and Drug Metabolism Programs Read More
from Marketwired News Releases
VistaGen Announces $36 Million Strategic Financing Agreement
April 10, 2013
Proceeds Will Accelerate Stem Cell Technology-Based Drug Rescue, Predictive Toxicology and Drug Metabolism Programs Read More
from Marketwired News Releases
Bergamo Acquisition Corp. Provides Authenticated Documentation to Confirm Bank Deposits
January 31, 2013
from Marketwired News Releases
L.L. Bradford Letter Confirms Funding Reported by Bergamo Acquisition Corp.
January 30, 2013
from Business Wire News Releases
Bergamo Acquisition Corp. Signs Investment Agreement
January 10, 2013
from Marketwired News Releases
Bergamo Acquisition Corp. Signs Investment Agreement
January 09, 2013
from Marketwired News Releases
QualityStocks Blog - Bergamo Acquisition Corp. (BGMO) Achieves Current Status on OTC Markets
December 13, 2012
from Latest Press Releases
Bergamo Acquisition Achieves Current Information Status on OTC Markets
December 11, 2012
from Marketwired News Releases
Bergamo Acquisition’s Corp Financials Filed with OTC Markets, the CEO Conducts Radio Interview Provides Further Update
November 16, 2012
from PR.com
Bergamo Acquisition's Corp Financials Filed with OTC Markets, the CEO Conducts Radio Interview Provides Further Update
November 13, 2012
from PRWeb
Bergamo Acquisition’s CEO Does Radio Interview - Provides Update
October 17, 2012
from Business Wire News Releases
Bergamo Acquisition Updates Financials
September 20, 2012
from Business Wire News Releases
YOUR OPINIONS ARE WRONG AGAIN
So far the shareholders have only heard opinions please provide links to back up your opinion that this time is no different.
There is plenty of evidence that this is very different ( including a Bank Statement filed with OTC markets, and a CPA letter verifying the Bank Statement )
Facts Below of what the CPA stated in his letter
How BGMO Secured USD 1,000,000,000.00 CASH FUNDING
1. HSBC Bank Statement posted on OTC MARKETS Filings on Jan 29th, 2013.
2. HSBC BANK A/C Holder’s Name.
3. HSBC BANK A/C Number.
4. HSBC BANK A/C Authorized Signatory.
5. HSBC BANK A/C Bank Officer Name and Title
6. HSBC BANK A/C Bank Officer Bank E-Mail Address.
7. HSBC BANK A/C 2nd BANK OFFICER Title and E-Mail Address
8. HSBC BANK A/C Main Branch Phone Number.
CPA ADMITS IN THE 1ST Line of his Letter JAN 25TH, 2013).
“QUOTE BY CPA” I am writing this letter at your request to (“VARIFY”) certain
Information CPA received during his meeting on Jan 23rd, 2013 with the management of Bergamo Acquisition Corp.
“QUOTE BY CPA” This letter can serve as a summary of the documents only as
“ADDITIONAL” information included in the originals agreements.
“QUOTE BY CPA” BGMO AFFILIATE WAS GRANTED USD 1,000,000,000.00
National Wealth Ltd.
“QUOTE BY CPA” NATIONAL WEALTH LTD was granted USD 1,000,000,000.00
On Jan 18, 2013. For a period of three years.
“QUOTE BY CPA” The Documents reference CASH deposit with HSBC totaling
USD 1,000,000,000.00.
“QUOTE BY CPA” Pursuant to the documents through a bond power, Deed of Assignment,
Bond Power hereby referred to as “Grantee” is National Wealth Ltd, Affiliate of Bergamo Acquisition Corp.
a) CPA Letter Dated Sep 19th, 2012
b) CPA Letter Dated Jan 25th, 2013
c) OTCMARKETS Filings Section, Review Bank Statement
d) OTCMARKETS Filings Section, Review powers authorized to the
“Grantee” which is National Wealth Ltd affiliate of Bergamo Acquisition Corp
e) Bank Statement is posted showing CASH deposit of USD 1,000,000,000.00.
f) Press Release Issued on Jan 10th, 2013 and Press Release Dated Jan 31st, 2013.
HSBC USD 1,000,000,000,00 ( DONE DEAL )
Certified Public Accountant Confirms Funding Reported by OTC BGMO
Direct Link on OTCMarkets: http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=98483
Documents are posted on the filings section, which can be found here: http://www.otcmarkets.com/stock/BGMO/filings
A challenge for anyone out there
If anyone can get any regulatory body to withdraw the bank statement or the financial statement from OTC markets, I will also go negative on BGMO
BUT THAT WILL NEVER HAPPEN, BECAUSE IT`S REAL !!!!
Certified Public Accountant Confirms Funding Reported by OTC BGMO
Direct Link on OTCMarkets: http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=98483
Documents are posted on the filings section, which can be found here: http://www.otcmarkets.com/stock/BGMO/filings
Got more cheap share !!!
Timing is everything !!!!
Gotta love this one !!!!
Breaking news in Nevada, Herzog is holding hostage the CPA from L.L. Bradford. He has a gun to his head and is forcing the CPA to sign a letter that verified the authenticity of the Bank Statement of BGMOs European subsidiary showing USD 1,000,000,000,00 at HSBC
HEHEHEHEHE
Got more cheap shares !!!!!
HSBC USD 1,000,000,000,00 ( DONE DEAL )
Certified Public Accountant Confirms Funding Reported by OTC BGMO
Direct Link on OTCMarkets: http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=98483
Documents are posted on the filings section, which can be found here: http://www.otcmarkets.com/stock/BGMO/filings
The billion dollar question is !!
When will BGMO close acquisitions, buy back,tender, and pay a dividend
That's when serious money will be made on the stock
Inquiring minds want to know
HSBC USD 1,000,000,000,00
Keep eyes open
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=98483
VSTA Uses Proprietary Stem Cell Technology to Address Two Separate Medical Needs
VistaGen Therapeutics is applying its innovative stem cell technologies in two separate but related fields. On the one hand, the company has developed one of the most important new approaches to the field of drug testing in decades, the use of stem cells to create their proprietary Human Clinical Trials in a Test Tube bioassay platform, which is designed to avoid the extensive time and expense involved in animal or other traditional tests. But VistaGen is also exploring a number of opportunities in the field of regenerative cell therapy, focused on blood, cartilage, heart, liver, and pancreas cells, each based on the proprietary stem cell differentiation and production capabilities of the company’s testing platform.
VistaGen’s stem cell based drug testing technology has resulted in CardioSafe 3D, a three-dimensional in vitro bioassay system for accurately assessing toxic (as well as non-toxic) effects of small-molecule drug candidates on human heart tissue. They are also finalizing the development of LiverSafe 3D, offering early and cost effective drug effect testing for the liver. VistaGen’s primary near-term goal for their testing technology is to use CardioSafe 3D, and eventually LiverSafe 3D, for drug rescue, to recapture substantial potential value associated with the pharmaceutical industry’s prior investment in drug discovery and development, involving once-promising small molecule drug candidates that were discontinued due to safety issues related to unexpected heart or liver toxicity or drug metabolism issues.
On the regenerative cell therapy side of things, VistaGen has developed AV-101, an orally available small molecule prodrug candidate, aimed at the needs of the multi-billion dollar neurological disease and disorders market. AV-101 has successfully completed Phase I development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system. Neuropathic pain affects approximately 1.8 million people in the U.S. alone. The company has already been awarded over $8.3 million of grant funding by the National Institutes of Health to support preclinical and Phase I clinical development of AV-101. The company believes that AV-101 may also be a candidate for development as a therapeutic alternative for depression, epilepsy, and Parkinson’s disease.
For additional information, visit www.VistaGen.com
It's not a matter of if BGMO will acquire approximately 70% of VSTA it just a matter of when.
We know the hold period of the of the initial profit of $88 million earned from the first tranche of investment funds of US $500 million will be up in a couple of months, but obviously BGMO and VSTA management believe the acquisition of VSTA will happen before then.
Quote:
In addition, the parties have agreed that no less than US $88 million, or its equivalent value in Euros, shall remain on deposit in the account of Bergamo Acquisition’s European subsidiary for a period of one year. This amount represents the initial profit earned from the first US $500 million cash-backed securities investments entered into between the parties previously, as set forth in Bergamo’s most recent consolidated financial report compiled by L.L. Bradford & Company LLC, a public accounting firm based in Nevada
Timing is everything
FACTS !!!!
Two questions all BGMO shareholders want answered.
1) How much money has BGMO made since September 17th
2) When will they have access to the money to close the VSTA and other acquisitions.
When we get the answer to question 2, BGMO will run like the proverbial scalded ape.
Timing is everything !!!!
VistaGen Provides Update on $36 Million Strategic Financing Agreement
Ticker Symbol: U:VSTA
SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/28/13
VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company applying pluripotent stem cell technology for drug rescue, predictive toxicology and drug metabolism assays, today announced an update on the status of its strategic financing agreement with Autilion AG.
Under the terms of the parties' April 2013 agreement, as amended, Autilion AG has committed to invest $36 million in VistaGen in consideration for 72 million shares of restricted VistaGen common stock, at a price of $0.50 per share, in a series of closings ending on or before September 30, 2013. The parties have amended their agreement, completed a first closing and scheduled additional closings to occur in July, August and September 2013. As noted previously, the self-placed strategic financing does not include warrants or investment banking fees.
Shawn K. Singh, VistaGen's Chief Executive Officer, stated, "I met with Autilion's team earlier this week, and we have been working closely with them since signing our agreement in April. We are confident and excited about completing this transformative financing. Building on the positive developments in our labs presented during the Annual Meetings of the Society of Toxicology and International Society of Stem Cell Research in March and this month, respectively, we look forward to accelerating our lead programs towards valuable outcomes for our shareholders."
Key information in the notes prepared by L.L.Bradford
1) During August 2012, a subsidiary (“Subsidiary”) of the Company entered into an Investors’ General Agreement and
Investment Platform Provider Business Agreement (hereafter the “Investor Agreement”). The Investor Agreement
describes the profit sharing between the investors and the Subsidiary and provides for weekly payment of those profits.
The agreement will be ongoing for five year
2) All profits generated from the use of the funds will be deposited in full to the bank of Bergamo’s European subsidiary company. These profits will be divided equally between National Wealth International Ltd. and the European subsidiary company of Bergamo Acquisition pursuant to the profit-sharing agreement between the parties.
3) Hillard Herzog, President and CEO of Bergamo, stated, “By contractual agreements, the funds deposited into our European subsidiary’s bank account are exclusively authorized for the investment program in place with National Wealth International. We requested examination by our corporate certified public accounting firm to erase any doubt that Bergamo Acquisition is able to move directly ahead with its investment program.”
4) L.L. Bradford has reviewed and verified all the original documents and the original bank deposit statement from HSBC. These original documents provided the location, account number and dollar value of deposits, and were signed & sealed by two bank officers for authenticity. L.L. Bradford finally confirmed Bergamo Acquisition’s current financial agreements. For further information on the recently announced investment agreement, review the press release issued by Bergamo Acquisition on January 10, 2013 (http://finance.yahoo.com/news/bergamo-acquisition-corp-signs-investment-165821767.html).
The letter of confirmation written by L.L. Bradford, together with redacted versions of all original documents reviewed by the CPA firm, has been posted on the OTC Markets website (www.otcmarkets.com/stock/BGMO/filings) as well as the website of Bergamo Acquisition (www.BergamoCorp.com). Bergamo Acquisition has posted redacted versions in conformity to nondisclosure and non-circumvent agreements with its partners.
The financial statements were prepared based on discussions with
you along with reviewing information and agreements you provided.
Hillard Herzog, CEO
Bergamo Acquisition Corp
Dear Mr. Herzog;
Included you will find the compiled financial statements of Bergamo Acquisition Corp as of and for the
period ended September 17, 2012. The financial statements were prepared based on discussions with
you along with reviewing information and agreements you provided. Thanks for giving us the
opportunity to serve Bergamo Acquisition Corporation. We look forward to working together in the
future.
Sincerely,
L.L. Bradford & Company, LLC
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=92173
THE INDEPENDENT ACCOUNTING FIRM OF L.L.BRADFORD WOULD NOT RISK THEIR BUSINESS LICENCE FOR HERZOG OR ANYONE ELSE BY PRODUCING A COMPILED FINANCIAL THAT IS ERRONEOUS OR MISLEADING
THERE IS THE PROOF BGMO HAS THE $88 MILLION AND MORE TO COME $$$$$$$$$
Bradford`s disclaimers in the cover letter does not give them legal right to produce a financial statement that is false or misleading
http://www.bullivant.com/Accountants-risks-presented-in-the-preparation
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=92172
Compiled financial statements, also referred to as unaudited statements, are not audited adequately and no opinion on the quality of the financial statements is given. Statements and guarantees about the accuracy of the financial statements are much less than that given by certified financial statements. Accountants that compile a company's financial statements are not required to verify or confirm the records and they do not need to analyze the statements for accuracy. However, in the event that an accountant finds erroneous, misleading or incomplete information in the financial statements they must notify management or abandon their involvement in assessing the company’s financial statements. The accountant who is appointed to compile a company’s financial statement must be familiar with the company and its main business processes.
I will believe ( and trust ) the independent accounting firm of L.L.BRADFORD on the numbers
THE NUMBERS DON'T LIE $$$$$$
( FACTS NOT OPINIONS )
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=92172
THE INDEPENDENT ACCOUNTING FIRM OF L.L.BRADFORD WOULD NOT RISK THEIR BUSINESS LICENCE FOR HERZOG OR ANYONE ELSE BY PRODUCING A COMPILED FINANCIAL THAT IS ERRONEOUS OR MISLEADING
For the period from January 1, 2012, through September 17, 2012, the company reported net income of $88,439,000, or $0.53 per share, on consolidated revenues of $283,952,000.
THERE IS THE PROOF BGMO HAS THE $88 MILLION AND MORE TO COME $$$$$$$$$
Bradford`s disclaimers in the cover letter does not give them legal right to produce a financial statement that is false or misleading
http://www.bullivant.com/Accountants-risks-presented-in-the-preparation
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=92172
Timing is everything !!!!
NOTES PREPARED BY THE INDEPENDENT ACCOUNTING FIRM OF L.L.BRADFORD
The Company is engaged in investing in financial instruments and companies worldwide. During May 2012, the
Company purchased 100% interest in a European entity for its investing strategies utilizing the EURO currency.
Note 2 – Investment in marketable securities
Investment in marketable securities consists of 2,132,157 shares of common stock in a publically traded company at a
cost of $1 million. During the period from January 1, 2012 through September 10, 2012, the Company recorded an
unrealized loss of $0.1 million. As of September 17, 2012, the estimated fair value of the shares was $0.9 million.
During August 2012, a Stock Purchase Agreement was entered into to purchase 60% of a Delaware corporation in
exchange for $7.5 million in order to effect the purchase of a majority control of the publically traded company noted in
the preceding paragraph. As of the date of these financials, the
Note 3 – Commitments and Contingencies
During September 2012, the Company entered into a settlement agreement to satisfy outstanding debt and accrued
interest carried on the Company’s financials at approximately $1.0 million. The Company had previously defended
against the penalties and interest but agreed to a total settlement of approximately $2.9 million. Accordingly, the
Company recorded settlement expense of $1.9 million.
During August 2012, a subsidiary (“Subsidiary”) of the Company entered into an Investors’ General Agreement and
Investment Platform Provider Business Agreement (hereafter the “Investor Agreement”). The Investor Agreement
describes the profit sharing between the investors and the Subsidiary and provides for weekly payment of those profits.
The agreement will be ongoing for five years.
Note 1 – Nature of Business and Summary of Significant Accounting Policies
The Company is engaged in investing in financial instruments and companies worldwide. During May 2012, the
Company purchased 100% interest in a European entity for its investing strategies utilizing the EURO currency.
Summary of Significant Accounting Policies
Basis of Presentation
These financial statements and related notes are presented in accordance with accounting principles generally accepted in
the United States. The Company’s fiscal year-end is December 31.
The Company’s reporting currency is the United States dollar (USD) and functional currency is the EURO. Foreign
currency assets and liabilities are translated into their U.S. dollar equivalents based on year end exchange rates. Revenue
and expense accounts are translated at average exchange rates. Aggregate exchange gains and losses arising from the
translation of foreign assets and liabilities are included in shareholders' equity as a component of comprehensive income.
Accumulated gain on foreign currency translation adjustment was
Cash and Cash Equivalents
Cash equivalents include money market accounts which have maturities of three months or less. For the purpose of the
statements of cash flows, all highly liquid investments with an original maturity of three months or less are considered to
be cash equivalents. Cash equivalents are stated at cost plus accrued interest, which approximates market value.
Revenue Recognition
Investments in Financial Instruments – The Company earns commissions based on returns from investments in financial
instruments. Revenues are recorded upon receipt of actual returns.
Costs include commissions or revenue sharing arrangements with other parties.
Fair Value of Financial Instruments
The Company’s financial instruments include cash, receivables, available-for-sale securities and due to related parties.
Management believes the fair values of these financial instruments approximate their carrying values due to their shortterm nature.
For the period from January 1, 2012, through September 17, 2012, the company reported net income of $88,439,000, or $0.53 per share, on consolidated revenues of $283,952,000.
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=92172
NOTES PREPARED BY THE INDEPENDENT ACCOUNTING FIRM OF L.L.BRADFORD
During August 2012, a subsidiary (“Subsidiary”) of the Company entered into an Investors’ General Agreement and
Investment Platform Provider Business Agreement (hereafter the “Investor Agreement”). The Investor Agreement
describes the profit sharing between the investors and the Subsidiary and provides for weekly payment of those profits.
The agreement will be ongoing for five years
“It is important to note L.L. Bradford has received and reviewed each and every document supplied by the Company as to its authenticity in preparation of this comprehensive report. We have provided all requested documentary evidence to support the information prepared.
September 19, 2012
Hillard Herzog, CEO
Bergamo Acquisition Corp
Dear Mr. Herzog;
Included you will find the compiled financial statements of Bergamo Acquisition Corp as of and for the
period ended September 17, 2012. The financial statements were prepared based on discussions with
you along with reviewing information and agreements you provided. Thanks for giving us the
opportunity to serve Bergamo Acquisition Corporation. We look forward to working together in the
future.
Sincerely,
L.L. Bradford & Company, LLC
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=92172
As real and true as the Heart Attack, that people who don`t own shares are going to have HEHEHEHE !!!!
The shareholders are in the middle of $88,439,000 net income and growing !!!!!
For the period from January 1, 2012, through September 17, 2012, the company reported net income of $88,439,000, or $0.53 per share, on consolidated revenues of $283,952,000.
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=92172
There is lots of money !!!!!!
Timing is everything !!!!!!!!
VSTA Offers Innovative Technological Solution to Ongoing Drug Discovery and Development Crisis
California based VistaGen Therapeutics, a biotech company focused on using their proprietary pluripotent stem cell technology for superior predictive toxicology and drug metabolism screening, is aggressively pursuing an innovative drug development path with unusually high profit potential. The company intends to identify once-promising small molecule drug candidates on which large amounts of research and development money has already been spent, but which have been discontinued and “shelved” due to unexpected safety concerns relating to heart or liver toxicity. The company’s one-of-a-kind bioassay platform, called Human Clinical Trials in a Test Tube, allows highly cost effective toxicity testing for heart and liver cells right in the laboratory, offering a unique way to quickly test and modify drug candidates, maintaining drug efficacy while eliminating toxicity.
VistaGen’s strategy leverages their developing stem cell technology based bioassay systems, CardioSafe 3D™ and LiverSafe 3D™, as well as their network of strategic relationships, and substantial prior third-party investment in drug discovery and development
The company’s approach is buoyed by the ongoing drug discovery and development crisis being experienced by the U.S. pharmaceutical industry. Last year, in spite of a $49 billion R&D investment by the pharmaceutical industry, the FDA’s Center for Drug Evaluation and Research approved only 39 novel NME (New Molecular Entity) drugs. Since 2003, the FDA has approved an average of only 26 NME’s annually. The high cost of drug development, coupled with this very low approval rate, means that such drug failures are a serious economic drain on the industry, and a potential economic catastrophe for the developing company.
A big part of the problem comes from known limitations of the industry’s current toxicological testing methodology, which relies primarily on animal models, transformed cell lines, or human cadaver cells. It’s an approach that can only approximate live human biology, and can lead to unpleasant surprises after millions or billions of dollars have already been spent on drug development.
VistaGen’s system offers mature human cells for more accurate and timely testing. It’s a technology of huge potential value to the industry, but also of value to VistaGen as a base for developing their own line of drug rescue variants.
For additional information, visit www.VistaGen.com
It's not a matter of if BGMO will acquire approximately 70% of VSTA it just a matter of when.
We know the hold period of the of the initial profit of $88 million earned from the first tranche of investment funds of US $500 million will be up in a couple of months, but obviously BGMO and VSTA management believe the acquisition of VSTA will happen before then.
Quote:
In addition, the parties have agreed that no less than US $88 million, or its equivalent value in Euros, shall remain on deposit in the account of Bergamo Acquisition’s European subsidiary for a period of one year. This amount represents the initial profit earned from the first US $500 million cash-backed securities investments entered into between the parties previously, as set forth in Bergamo’s most recent consolidated financial report compiled by L.L. Bradford & Company LLC, a public accounting firm based in Nevada
Timing is everything
FACTS !!!!
Shareholders have 432 questions, we are looking for answers from the brains of the operation, not the ventriloquists.
YOUR OPINIONS ARE WRONG AGAIN
So far the shareholders have only heard opinions please provide links to back up your opinion that this time is no different.
There is plenty of evidence that this is very different ( including a Bank Statement filed with OTC markets, and a CPA letter verifying the Bank Statement )
How BGMO Secured USD 1,000,000,000.00 CASH FUNDING
1. HSBC Bank Statement posted on OTCMARKETS Filings on Jan 29th, 2013.
2. HSBC BANK A/C Holder’s Name.
3. HSBC BANK A/C Number.
4. HSBC BANK A/C Authorized Signatory.
5. HSBC BANK A/C Bank Officer Name and Title
6. HSBC BANK A/C Bank Officer Bank E-Mail Address.
7. HSBC BANK A/C 2nd BANK OFFICER Title and E-Mail Address
8. HSBC BANK A/C Main Branch Phone Number.
YOU'RE WRONG AGAIN, HEARD IT ALL BEFORE ( YAWN )
HSBC USD 1,000,000,000,00 ( DONE DEAL )
Certified Public Accountant Confirms Funding Reported by OTC BGMO
Direct Link on OTCMarkets: http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=98483
Documents are posted on the filings section, which can be found here: http://www.otcmarkets.com/stock/BGMO/filings
There are lies being told but not by HH/SP the lies are coming from 2009 con man group and one grumpy old man LOL !!!!!!
$88,439,000 net income and growing !!!!!
For the period from January 1, 2012, through September 17, 2012, the company reported net income of $88,439,000, or $0.53 per share, on consolidated revenues of $283,952,000.
http://www.otcmarkets.com/financialReportViewer?symbol=BGMO&id=92172
Timing is everything !!!!!!!!